FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIA	L OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

															_					
1. Name and Address of Reporting Person* <u>Bowden Christopher</u>				2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO									(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (speci						
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 01/20/2019										X Officer (give fine Other (specify below) Chief Medical Officer					
(Street)	DGE N	MA	02	2139		4. If <i>i</i>	Ameno	lment	t, Date of	f Original	Filed	(Month/Da	y/Year)		6. Ind Line)	Form fi	led by One led by Mor	Repo	(Check Aporting Person One Report	n
(City)	(:	State)	`																	
Date			2. Transa	action 2A. De Execu Day/Year) if any		A. Deemed execution Date,		3. 4. Securitie Disposed Code (Instr.		ies Acquired (A) of (D) (Instr. 3, 4		A) or	5. Amour Securitie Beneficia	nt of	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or	Price	Reported Transact (Instr. 3 a	ction(s)			(Instr. 4)	
Common stock 01/20/				2019		M		6,265	6,265 A		(1)	7,189			D					
Common stock 01/22/2				2/2019				F		1,960 D		\$52.82	5,229			D				
			Та									osed of, convertil			-	Owned				
1. Title of Derivative Security (Instr. 3) (Instr. 3) 2. Conve or Exe Price of Derivas Security		on Da se (M	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transactic (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	O N	Amount or Number of Shares					
Performance	(1)		01/20/2019			M			6,265	(2)		(2)	Commo	n	6,265	\$0.00	0		D	

Explanation of Responses:

- 1. Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

William Cook, as Attorney-infact for Christopher Bowden

01/23/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.